Q1 2022 Results
Company overview
Financial review
Financial performance
CRM
Immunology
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
References
Abbreviations
Hematology
Biosimilars
Global Health
Entresto® - Angiotensin receptor/neprilysin inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03785405 (CLCZ696B2319E1 - extension study)
Heart failure in pediatric patients
Phase 3
240
Number of participants with Adverse Events (AEs) and Serious Adverse Events
(SAEs)
Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5,
31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and
adult formulation (50, 100, 200 mg bid))
Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction
who have completed study CLCZ696B2319
Target Patients
Read-out Milestone(s)
2023
Publication
TBD
47 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation